Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo

Komen, L.; Graca, V. da; Wolkerstorfer, Albert; Rie, Menno A. de; Terwee, Caroline B.; Veen, J.P.W. van der

doi:10.1111/bjd.13432

Cited by 65 publications

(70 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The VASI was calculated using a formula for summing all body areas (by hand unit) according to level of depigmentation . Disease activity was classified into three groups as progressive, regressive, or stable.…”

Section: Methodsmentioning

confidence: 99%

Effects of age of onset on disease characteristics in non‐segmental vitiligo

et al. 2017

View full text Add to dashboard Cite

In patients with vitiligo, the clinical and laboratory features of the disease may vary according to time of onset. This is addressed in the literature by only a few studies with conflicting results. The aim of this study was to determine the demographic and clinical features of patients with non-segmental vitiligo and to establish the association between vitiligo and autoimmune diseases with a focus on time of disease onset. A total of 224 vitiligo patients for whom complete medical records were available were evaluated retrospectively. Demographic data, scores on the Vitiligo Area Score Index (VASI), clinical features, vitiligo disease activity, repigmentation status, presence of any accompanying autoimmune disease, antinuclear antibody (ANA) titers, serum levels of glucose, thyroid-stimulating hormone (TSH), thyroxine (T4) hormone, anti-thyroid peroxidase (anti-TPO), and anti-thyroglobulin (anti-TG) were recorded. The prevalence of halo nevi was significantly higher (P < 0.001) among children than in other patient groups. The prevalence of leukotrichia was higher in adults with adult-onset disease than in either pediatric patients or adults with childhood-onset disease (P = 0.002). Both anti-TG and anti-TPO levels were significantly higher in adults with adult-onset disease than in pediatric patients and adult patients with childhood-onset disease. The prevalence of autoimmune disease was 22.2%. Anti-TG levels were significantly higher in patients with treatment-related repigmentation than in those without repigmentation. This study shows that clinical features and associations with autoimmune disease may vary according to the age of onset of vitiligo.

show abstract

Section: Methodsmentioning

confidence: 99%

Effects of age of onset on disease characteristics in non‐segmental vitiligo

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The VASI relies on an estimation of affected BSA, with limited sensitivity to change (>4.7% BSA). 5 Newer outcome measures may provide more sensitive options for monitoring responses. Simvastatin may induce myopathy at higher doses; however, topical treatment may allow the delivery of sufficiently high local concentrations without systemic toxicity and could be tested in larger studies.…”

Section: To the Editormentioning

confidence: 99%

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Vanderweil

Amano

et al. 2017

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…A common misconception is that biomarkers of treatment response are unnecessary, since the skin can be observed clinically; however, even the earliest clinical changes in vitiligo take 2-3 months to become apparent due to the time required for melanocyte precursors to proliferate, migrate, differentiate, and produce pigment. Measurable responses require 6 months or more, and current outcome measures are largely subjective and insensitive to small changes 8,9 . Thus, relying only on observable changes in skin pigmentation is problematic.…”

Section: Introductionmentioning

confidence: 99%

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity

Strassner

Rashighi

Refat

et al. 2017

Journal of the American Academy of Dermatology

101

View full text Add to dashboard Cite

Background Vitiligo is an autoimmune disease of the skin with limited treatment options; there is an urgent need to identify and validate biomarkers of disease activity to support vitiligo clinical studies. Objective To investigate potential markers of disease activity directly in the skin of vitiligo subjects and healthy subjects. Methods Patient skin was sampled via a modified suction blister technique allowing for minimally invasive, objective assessment of cytokines and T cell infiltrates in interstitial skin fluid. Potential biomarkers were first defined and later validated in separate study groups. Results In screening and validation, CD8+ T cell number and CXCL9 protein concentration were significantly elevated in active lesional compared to non-lesional skin. CXCL9 protein concentration achieved greater sensitivity and specificity by ROC analysis. Suction blistering also allowed for phenotyping of the T cell infiltrate, which overwhelmingly expresses CXCR3. Limitations A small number of patients were enrolled for the study, including a single patient to define the treatment response. Conclusion Measuring CXCL9 directly in the skin may be effective in clinical trials as an early marker of treatment response. Additionally, use of the modified suction blister technique supports investigation of inflammatory skin diseases using powerful tools like flow cytometry and protein quantification.

show abstract

Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo

Cited by 65 publications

References 31 publications

Effects of age of onset on disease characteristics in non‐segmental vitiligo

Effects of age of onset on disease characteristics in non‐segmental vitiligo

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity

Contact Info

Product

Resources

About